Revisiting the role of tumor necrosis factor α and the response to surgical injury and inflammation

Archives of Surgery

Volumn 133, Issue 5, 1998, Pages 558-567

  Ksontini, Riadh ^a   MacKay, Sally L D ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DISEASE ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; SEPTIC SHOCK; SURGICAL INJURY;

APOPTOSIS; HUMANS; INFLAMMATION; INTRAOPERATIVE COMPLICATIONS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031955230     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.133.5.558     Document Type: Article

References (113)

1. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986;320:584-588.
2. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense. Shock. 1995; 3:1-12.
3. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 1990;145:3762-3766.
4. Feldmann M, Brennan FM, Elliot MJ, Williams RO, Maini RN. TNF alpha is a therapeutic target for rheumatoid arthritis. Ann N Y Acad Sci. 1995; 766:272-278.
5. Raine CS. Multiple sclerosis: TNF revisited, with promise. Nature Med. 1995;1:211-214.
6. Brynskov J, Nielson OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis. 1994;12: 290-304.
7. Famularo G, De Simone C, Tzantzoglou S, Trinchieri V. Apoptosis, anti-apoptotic compounds and TNF-α release. Immunol Today. 1994;15:495-496.
8. Ware CF, VanArsdale S, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem. 1996;60: 47-55.
9. Wang CY, Mayo MW, Baldwin ASJ. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB [see comments]. Science. 1996;274:784-787.
10. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66:181-196.
11. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/ tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167: 1211-1227.
12. Tracey KJ, Lowry SF, Fahey TJ, et al. Cachectin/ tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164:415-422.
13. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977-980.
14. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989;170: 1627-1633.
15. Tracey KJ, Fong Y, Hesse DG, et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330: 662-664.
16. Hinshaw LB, Tekamp Olson P, Chang AC, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock. 1990;30:279-292.
17. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992;148:2724-2730.
18. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock. 1995;4:89-95.
19. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis. 1991; 163:83-88.
20. Bone RC. Sepsis and controlled clinical trials: the odyssey continues. Crit Care Med. 1995;23: 1313-1315.
21. Bone RC. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS): Gulliver in Laputa. JAMA. 1995;273:155-156.
22. Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA. 1997;277:1531-1538.
23. Fisher CJ Jr, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis: the CB0006 Sepsis Syndrome Study Group [see comments]. Crit Care Med. 1993; 21:318-327.
24. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995;273: 934-941.
25. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
26. Baue AE. Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome: why no magic bullets? Arch Surg. 1997;132:703-707.
27. Rogy MA, Coyle SM, Oldenburg HS, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg. 1994; 178:132-138.
28. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
29. Pruitt JH, Welborn MB, Edwards PD, et al. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood. 1996;87: 3282-3288.
30. Suter PM, Suter S, Girardin E, Roux Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis. 1992;145:1016-1022.
31. Holzheimer RG, Schein M, Wittmann DH. Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Arch Surg. 1995;130:1314-1319.
32. Asnkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. 1991;88:10535-10539.
33. Haak Frendscho M, Marsters SA, Mordenti J, et al. Inhibition of TNF by a TNF receptor immunoadhesin: comparison to an anti-TNF monoclonal antibody. J Immunol. 1994;152:1347-1353.
34. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
35. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997; 337:141-147.
36. Han J, Brown T, Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level [published erratum appears in J Exp Med. 1990;171:971-972]. J Exp Med. 1990;171:465-475.
37. Moss ML, Catherine-Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature. 1997;385:733-736.
38. Black RA, Ruach CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997;385: 729-732.
39. van der Poll T, Calvano SE, Kumar A, et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood. 1995; 86:2754-2759.
40. van der Poll T, Jansen J, van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis. 1993;168:955-960.
41. van der Poll T, van Deventer SJ, ten Cate H, Levi M, ten Cate JW. Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis. 1994; 169:665-667.
42. van der Poll T, Galvano SE, Kumar A, et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood. 1995; 86:2754-2759.
43. van der Poll T, Fischer E, Coyle SM, et al. Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. J Infect Dis. 1995;172:577-580.
44. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int Immunol. 1995;7:517-523.
45. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor alpha in human monocyte IL-10 synthesis. J Immunol. 1996;151: 6853-6861.
46. van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol. 1991; 261:E457-E465.
47. 2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985; 62:2163-2168.
48. van der Poll T, Jansen J, Levi M, ten-Cate H, ten-Cate JW, van Deventer SJ.. Regulation of interleukin-10 release by tumor necrosis factor-alpha in humans and chimpanzees. J Exp Med. 1994;180:1985-1988.
49. van der Poll T, Jansen PM, Montegut WJ, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol. 1997;158:1971-1975.
50. Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood. 1996;87:4261-4275.
51. Wang SD, Huang KJ, Lin YS, Lei HY. Sepsis-induced apoptosis of the thymocytes in mice. J Immunol. 1994;152:5014-5021.
52. Liles WC, Klebanoff SJ. Regulation of apoptosis in neutrophils: Fas track to death? J Immunol. 1995;155:3289-3291.
53. Ayala A, Herdon CD, Lehma DL, Ayala CL, Chaudry IH. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood. 1996;87:4261-4275.
54. Haendeler J, Messmer UK, Brune B, Neugebauer E, Dimmeler S. Endotoxic shock leads to apoptosis in vivo and reduces Bcl-2. Shock. 1996; 6:405-409.
55. Buchman TG, Abello PA, Smith EH, Bulkley GB. Induction of heat shock response leads to apoptosis in endothelial cells previously exposed to endotoxin. Am J Physiol. 1993;265:H165-H170.
56. Hiramatsu M, Hotchkiss RS, Karl IE, Buchman TG. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway. Shock. 1997;7:247-253.
57. Bohlinger I, Leist M, Gantner F, Angermuller S, Tiegs G, Wendel A. DNA fragmentation in mouse organs during endotoxic shock. Am J Pathol. 1996;149:1381-1393.
58. Kolberg R. Tangled pathways: new roles for NF-κB, TNF-α in apoptosis. J Natl Inst Health Res. 1997;9:29-32.
59. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNFα-induced cell death. Science. 1996;274:782-784.
60. Van Antwerp DJ, Seamus JM, Kafri T, Green D, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-κB. Science. 1996;274:787-789.
61. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784-787.
62. Barinaga M. Life-death balance within the cell. Science. 1997;274:724.
63. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A. 1991;88:9292-9296.
64. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87: 3127-3131.
65. Grell M, Zimmermann G, Hülser D, Pfizenmaier K, Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol. 1994;153:1963-1972.
66. Malinin NL, Boldin MP, Kovalenko AW, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature. 1997; 385:540-544.
67. Van Zee KJ, Stackpole SA, Montegut WJ, et al. A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J Exp Med. 1994; 179:1185-1191.
68. Welborn MB III, Van Zee K, Edwards PD, et al. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med. 1996;184:165-171.
69. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med. 1995;181: 607-617.
70. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798-802.
71. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372:560-563.
72. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793-802.
73. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.
74. Keogh C, Fong Y, Marano MA, et al. Identification of a novel tumor necrosis factor alpha/ cachectin from the livers of burned and infected rats. Arch Surg. 1990;125:79-84.
75. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med. 1994;180:2173-2179.
76. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem. 1993;268:18542-18548.
77. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-329.
78. Solorzano CC, Ksontini R, Pruitt JH, et al. Involvement of 26kD cell-associated TNF in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol. 1997;158:414-419.
79. Solorzano CC, Ksontini R, Pruitt JH, et al. A matrix metalloproteinase inhibitor prevents processing of TNFα and abrogates endotoxin-induced lethality. Shock. 1997;7:427-431.
80. Espat NJ, Cendan JC, Beierle EA, et al. PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J Surg Res. 1995;59: 153-158.
81. Georgopolous S, Plows D, Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm. 1996;46:86-97.
82. Eissner G, Kohlhuber F, Grell M, et al. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood. 1995;86:4184-4193.
83. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol. 1995; 154:1307-1316.
84. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996; 334:1717-1723.
85. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1455.
86. Zhou T, Edwards CKI, Evans RJ, Bluethmann H, Mountz JD. Fas and tumor necrosis factor receptor I mediated activation induced cell death of macrophages. J Immunol. In press.
87. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996;184: 429-440.
88. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 1993;74:845-853.
89. Chinnaiyan A, O'Rourke K, Yewari M, Dixit V. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505-512.
90. Stanger B, Leder P, Lee T, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 1995;81:513-523.
91. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell. 1995;81:495-504.
92. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299-308.
93. Vandenabeele P, Declercq W, Vanhaesebroeck B, Grooten J, Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol. 1995;154:2904-2913.
94. Bigda J, Beletsky I, Brakebusch C, et al. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med. 1994;180: 445-460.
95. Yuan J, Shaham S, Ledoux S, Ellis H, Horvitz R. The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1beta converting enzyme. Cell. 1993;75:641-652.
96. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/ced-3 protease nomenclature. Cell. 1996;87:171.
97. Fraser A, Evan G. A license to kill. Cell. 1996;85: 781-784.
98. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997;386:619-623.
99. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/ FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 1996;85: 803-815.
100. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/0CED-3-like proteinase is recruited to the CD95(Fas/ APO-1) death-inducing signaling complex. Cell. 1996;85:817-827.
101. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387-396.
102. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 1996;271:4961-4965.
103. Duan H, Dixit VM. RAIDD is a new "death" adaptor molecule. Nature. 1997;385:86-89.
104. Livesay JJ, Cooley DA, Ventermiglia RA, et al. Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. Ann Thorac Surg. 1985;39:37-45.
105. Rodriguez I, Matsura K, Ody C, Nagata S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fuliminant liver destruction and death. J Exp Med. 1996;184:2067-2072.
106. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806-809.
107. Hengartner MO, Horvitz HR. C elegans cell survival gene ced-9 encodes a functional homolog of the mammalian protooncogene bcl-2. Cell. 1994;76:665-676.
108. Itoh N, Tsujimoto Y, Nagata S. Effect of Bcl-2 on Fas antigen-mediated cell death. J Immunol. 1993;151:621-627.
109. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xl. Immunity. 1995;3:87-88.
110. Rodriguez I, Matsura K, Khatib K, Reed J, Nagata S, Vassalli P. A bel-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med. 1996; 183:1031-1036.
111. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 1997;89:175-184.
112. Baldwin ASJ. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
113. Böhrer H, Qiu F, Zimmermann T, et al. The role of NF-κB in the mortality of sepsis. J Clin Invest. 1997;100:972-985.